MARKET

IMGN

IMGN

Immunogen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.680
+0.210
+6.05%
After Hours: 3.760 +0.08 +2.17% 19:31 05/26 EDT
OPEN
3.480
PREV CLOSE
3.470
HIGH
3.760
LOW
3.451
VOLUME
4.42M
TURNOVER
0
52 WEEK HIGH
7.77
52 WEEK LOW
3.360
MARKET CAP
811.57M
P/E (TTM)
-6.1364
1D
5D
1M
3M
1Y
5Y
BRIEF-Immunogen Presents Additional Efficacy And Safety Analyses Evaluating Mirvetuximab Soravtansine In Ovarian Cancer At Asco
reuters.com · 2h ago
ImmunoGen Says More Than 70% of Ovarian Cancer Patients Showed Tumor Reduction in Mirvetuximab Soravtansine Study
MT Newswires · 8h ago
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Zacks · 2d ago
What's Going On With ImmunoGen Shares Today?
ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.
Benzinga · 3d ago
INO, WWR and CTIC among pre market gainers
GeoVax Labs (GOVX) +20%. Inovio Pharmaceuticals (INO) +19%. SIGA Technologies (SIGA) +15% Monkeypox plays indicate further upside as global toll climbs. O2Micro International (OIIM) +13%. GoldMining (GLDG) +12%. Emergent BioSolutions (EBS) +12% Monkeypox p...
Seekingalpha · 3d ago
ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy
Shares of ImmunoGen Inc. jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription...
marketwatch.com · 3d ago
ImmunoGen ovarian cancer therapy undergoes FDA priority review
The clinical-stage biotech, ImmunoGen (NASDAQ:IMGN) announced on Monday that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its ovarian cancer therapy mirvetuximab soravtansine under
Seekingalpha · 3d ago
ImmunoGen Announces Acceptance Of Biologics License Application For Mirvetuximab Soravtansine In Ovarian Cancer By US FDA With Priority Review
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the
Benzinga · 3d ago
More
No Data
Learn about the latest financial forecast of IMGN. Analyze the recent business situations of Immunogen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
30.00%Buy
30.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IMGN stock price target is 12.00 with a high estimate of 20.00 and a low estimate of 4.000.
High20.00
Average12.00
Low4.000
Current 3.680
EPS
Actual
Estimate
-1.37-1.03-0.68-0.34
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 326
Institutional Holdings: 204.88M
% Owned: 92.90%
Shares Outstanding: 220.54M
TypeInstitutionsShares
Increased
73
19.89M
New
29
8.14M
Decreased
61
10.44M
Sold Out
42
12.90M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Mccluski
President/Chief Executive Officer/Director
Mark Enyedy
Chief Financial Officer/Senior Vice President
Susan Altschuller
Senior Vice President
Anna Berkenblit
Senior Vice President
Stacy Coen
Senior Vice President
Kristen Harrington-smith
Senior Vice President
Mimi Huizinga
Senior Vice President
Theresa Wingrove
Independent Director
Stuart Arbuckle
Independent Director
Mark Goldberg
Independent Director
Tracey Mccain
Independent Director
Dean Mitchell
Independent Director
Kristine Peterson
Independent Director
Helen Thackray
Independent Director
Richard Wallace
No Data
No Data
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Its Mirvetuximab soravtansine is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. IMGN632 is an ADC comprised of a high-affinity antibody designed to target CD123 for patients with hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.